Health Care

Explore how Anavex Life Sciences’ partnership with ACCESS‑AD could fast‑track blarcamesine—its sigma‑1 receptor drug—into a potential first‑in‑class Alzheimer’s therapy, boosting investor confidence and shaping future CNS precision medicine.

UniQure NV (QURE) – gene‑therapy stock with Overweight support, a robust pipeline, and legal scrutiny; is it a high‑reward opportunity or risk?

Beyond Air’s $32 M NeuroNOS sale sparks a 165 % stock spike, funding its respiratory focus while eyeing lucrative autism therapy—an enticing, volatile biotech play.

Discover how Sartorius AG’s new sustainability certification and bio‑circular product launch could reshape its ESG standing, investor confidence, and future growth prospects.

CVS Health’s new $91 target from Bernstein shows bullish outlook amid insider‑trading probe—explore how its diversified pharmacy‑benefit model drives future growth.

Avadel Pharmaceuticals PLC shares hit $21.50 as shareholders approve a strategic acquisition, with major investors like Vanguard and State Street filing 1%+ stake disclosures under the Irish Takeover Panel Act, signaling a potential market shift for…

Fate Therapeutics boosts talent retention with new employee awards, underscoring its role in advancing stem‑cell regenerative medicine while navigating biotech valuation challenges.

Ionis Pharmaceuticals doubles Tryngolza sales forecast to $2 billion, positioning itself for robust 2026 growth amid a strong antisense oligonucleotide launch and strategic partnerships.

Lexicon Pharmaceuticals updates its biopharma pipeline at J.P. Morgan Healthcare, highlighting breakthrough treatments for diabetes, obesity, and cancer—showing strong innovation despite current financial volatility.

Lexaria Bioscience’s 2025 breakthrough in oral GLP‑1 delivery with DehydraTECH™ positions the company to capture a booming market, unlocking new therapeutic avenues for investors.